ZENI: Revenue growth and positive operating income mark a strong Q3, despite liquidity challenges

About this update from Zenicor Medical Systems Ab

Q3 2024 saw 4% revenue growth and a return to positive operating income, with EBITDA at 1,104 KSEK. Liquidity remains a challenge, but new contracts and ongoing projects support a positive outlook.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Zenicor Medical Systems Ab